Compare PBHC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBHC | LUNG |
|---|---|---|
| Founded | 1859 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.2M | 72.2M |
| IPO Year | 2014 | 2020 |
| Metric | PBHC | LUNG |
|---|---|---|
| Price | $13.62 | $1.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.81 |
| AVG Volume (30 Days) | 3.2K | ★ 365.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ 46.25 | 10.00 |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | ★ $83,789,000.00 |
| Revenue This Year | N/A | $9.21 |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | $29.03 | ★ N/A |
| Revenue Growth | N/A | ★ 22.01 |
| 52 Week Low | $12.06 | $1.31 |
| 52 Week High | $17.00 | $8.10 |
| Indicator | PBHC | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 51.24 |
| Support Level | $13.43 | $1.51 |
| Resistance Level | $13.75 | $1.69 |
| Average True Range (ATR) | 0.17 | 0.13 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 87.40 | 56.94 |
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.